Clinical trial · Interventional
Personalised Postoperative Radiochemotherapy in Patients With Head and Neck Cancer
Personalised Postoperative Radiochemotherapy in Patients With Head and Neck Cancer and Development of a Multi-parametric Decision Support System for Personalised Medicine in Radiation Oncology
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The current trial is evaluating the integration of a pretherapeutical FDG-PET/MRI in the adjuvant radiochemotherapy in patients with head and neck cancer. As a secondary hypothesis the intention is to develop of a multi-parametric decision support system for personalised medicine by integrating functional imaging, γH2AX-analysis and genetic information.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Integration of PET/MRI in radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Integration of PET/MRI in radiotherapy
- description
- Integration of pretherapeutical PET/MRI in adjuvant radiotherapy
- interventionNames
- Radiation: Integration of PET/MRI in radiotherapy
Primary outcomes (1)
- measure
- locoregional progression free survival
- timeFrame
- 2 years after primary diagnosis
- description
- 15% improvement in loco-regional PFS at 2 years through integrtion of pre-operative PET/MR imaging into RT treatment planning
Secondary outcomes (3)
- measure
- Disease free survival
- timeFrame
- 2 years after primary diagnosis
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * locally-advanced HNSCC (Oro- and Hypopharynx) stage III and IV without distant metastases * no contraindications for PET/MRI * no contraindications for radiochemotherapy * informed consent * ECOG PS 0/2 Exclusion Criteria: * Secondary malignancies that might influence outcome within 2 years after radiochemotherapy of the HNSCC * previous PET/CT * induction therapy * pregnancy or breastfeeding
References
Publications (0)
Data not yet available